New cancer drug trial halted early – what we know

NCT ID NCT06779851

Terminated Disease control Sponsor: Bright Peak Therapeutics Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug called BPT567 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to help the immune system fight cancer by targeting PD-1 and delivering an immune-boosting protein (IL-18). The main goals were to check safety, find the right dose, and see if the drug shrinks tumors. The study was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Carolina BioOncology Institute

Huntersville, North Carolina, 28078, United States
Hackensack Meridian John Theurer Cancer Center

Hackensack, New Jersey, 07601, United States
Honor Health Research Institute

Scottsdale, Arizona, 85260, United States
Providence Cancer Institute

Portland, Oregon, 97213, United States
South Texas Accelerated Research Therapeutics (START)

San Antonio, Texas, 78229, United States
Start Midwest

Grand Rapids, Michigan, 49546, United States
University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.